Yes ⊠ No □

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-0

| (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE For the quarterly period ended | |
|---|--|
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE | |
| For the quarterly period ended | March 31, 2024 |
| | |
| OR | |
| ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH | E SECURITIES EXCHANGE ACT OF 1934 |
| For the transition per | |
| Commission file number | 000-56342 |
| VERANO HOLDIN | GS CORP. |
| (Exact name of registrant as spec | ified in its charter) |
| British Columbia, Canada | 98-1583243 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 224 W Hill Street, Suite 400, Chicago, Illinois | 60610 |
| (Address of Principal Executive Offices) | (Zip Code) |
| (312) 265-0730 | |
| (Registrant's telephone number, inc | cluding area code) |
| N/A | |
| (Former name, former address and former fiscal y | /ear, if changes since last report) |
| Securities registered pursuant to Section 12(b) of the Act: | |
| Title of each class Trading Symbol | Name of each exchange on which registered |
| N/A N/A | N/A |
| Indicate by check mark whether the registrant: (1) has filed all reports required to be during the preceding 12 months (or for such shorter period that the registrant was requirements for the past 90 days. Yes ⊠ No □ Indicate by check mark whether the registrant has submitted electronically every Interaction. | equired to file such reports); and (2) has been subject to such filing |

Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Table of Contents

| 2 2 2 | th company. See the definitions of 'ule 12b-2 of the Exchange Act. | 'large accelerated fil | er," "accelerated filer," "smaller reporting co | ompany," and "emerging growth |
|------------------|--|------------------------|--|-------------------------------|
| | Large accelerated filer | \boxtimes | Accelerated filer | |
| | Non-accelerated filer | | Smaller reporting company | |
| | | | Emerging growth company | |
| or revised finan | icial accounting standards provided pur | rsuant to Section 13(a | s elected not to use the extended transition peri) of the Exchange Act. □ d in Rule 12b-2 of the Exchange Act). Yes □ N | |
| As of May 6, 20 | 024, the registrant had 344,163,149 Cla | ss A subordinate voti | ing shares and no Class B proportionate voting | shares outstanding. |
| | | | | |
| | | | ii | |

TABLE OF CONTENTS

| | | Pages |
|-----------------------|--|-----------|
| Part I - Financial Ir | <u>iformation</u> | <u>1</u> |
| Item 1. | Unaudited Interim Condensed Consolidated Financial Statements | <u>1</u> |
| | Condensed Consolidated Balance Sheets | <u>2</u> |
| | <u>Unaudited Interim Condensed Consolidated Statements of Operations</u> | <u>3</u> |
| | Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity | <u>4</u> |
| | Unaudited Interim Condensed Consolidated Statements of Cash Flows | <u>5</u> |
| | Notes to Unaudited Interim Condensed Consolidated Financial Statements | <u>6</u> |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>27</u> |
| <u>Item 3.</u> | Quantitative and Qualitative Disclosures About Market Risk | <u>35</u> |
| <u>Item 4.</u> | Controls and Procedures | <u>35</u> |
| Part II - Other Info | <u>rmation</u> | <u>36</u> |
| <u>Item 1.</u> | <u>Legal Proceedings</u> | <u>36</u> |
| Item 1A. | Risk Factors | <u>36</u> |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | <u>36</u> |
| <u>Item 3.</u> | <u>Defaults Upon Senior Securities</u> | <u>36</u> |
| <u>Item 4.</u> | Mine Safety Disclosures | <u>36</u> |
| <u>Item 5.</u> | Other Information | <u>36</u> |
| <u>Item 6.</u> | <u>Exhibits</u> | <u>37</u> |
| <u>Signatures</u> | | <u>38</u> |

i

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Form 10-Q") contains "forward-looking information" and "forward-looking statements" within the meaning of United States securities laws (together, "forward-looking statements"). All statements, other than statements of historical fact, made by the Company or its affiliates that address activities, events or developments that the Company or its affiliates expect or anticipate will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as "may," "will," "would," "should," "believes," "assumes," "estimates," "projects," "potential," "expects," "plans," "intends," "anticipates," "targeted," "continues," "forecasts," "designed," "goal," "progress," or the negative of those words or other similar or comparable words.

The forward-looking statements contained herein are based on certain key expectations and assumptions, including, but not limited to, expectations and assumptions concerning:

- our ability to obtain, maintain and renew licenses and other regulatory approvals in all states and localities of our operations and planned operations on a timely basis;
- government regulations, including future U.S. state and federal legislative and regulatory developments involving medical and adult-use cannabis and the timing thereof;
- our outlook on our expansion and growth of business and operations;
- our ability to achieve our goals, business plans and strategy;
- our ability to access capital and obtain necessary financing to pursue our growth and business plans;
- our operational results and other financial and business conditions and prospects;
- the timing and completion of acquisitions and other commercial transactions;
- the integration and operation of acquired businesses;
- · the timing and amount of capital expenditures;
- the availability of facilities, equipment, skilled labor and services needed for cannabis operations;
- demand, developments and trends in the medical and adult-use cannabis industry;
- competition in the cannabis industry in the markets in which we operate or plan to operate;
- the medical benefits, viability, safety, efficacy, and dosing of cannabis;
- · the size of the medical cannabis market and the adult-use cannabis market in each state; and
- conditions in general economic and financial markets.

Forward-looking statements may relate to future financial conditions, results of operations, plans, strategies, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then-current expectations of the party making the statement and assumptions concerning future events, which are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to:

- the illegality of cannabis under federal law, the U.S. federal regulatory landscape and enforcement related to medical or adult-use cannabis, including political risks, civil asset forfeiture and regulation by additional regulatory authorities;
- regulatory and political changes to U.S. federal, state and local laws related to medical or adult-use cannabis, including political risks and regulation by additional regulatory authorities;
- our limited operating history;
- the impacts of economic uncertainty stemming from disruptions in U.S. and global markets, inflation, rising interest rates, and changes in consumer and business confidence;
- our outstanding indebtedness and potential future indebtedness;
- any potential changes in our liquidity due to potential for instability in market and economic conditions and adverse developments to financial institutions;
- reliance on key management;
- market acceptance of existing and new products and potential returns or recalls of our products;
- customer acceptance of our brand portfolio;
- the accuracy of our forecasted demand for our products;
- the potential for fraudulent activity by employees, contractors and consultants;
- our exposure to growth-related operational and execution risks;
- potential negative findings in our clinical research with respect to our products;
- our ongoing litigation matter with Goodness Growth Holdings, Inc;

- potential product liability claims;
- our exposure to natural phenomena and resulting potential uninsured or under insured losses;
- our structure and our resulting reliance on the performance of our subsidiaries and affiliates;
- our expansion-by-acquisition strategy;
- our ability to acquire businesses and cannabis licenses in desired markets and the integration and operation of acquired businesses;
- the typically limited operations of businesses we acquire;
- the unconventional due diligence process in the cannabis industry;
- our ability to acquire and lease properties suitable for the cultivation, production and sale of cannabis;
- potential limited representations and warranties of businesses we may acquire;
- our acquisition of businesses in developing cannabis markets;
- our lack of portfolio diversification;
- our use of joint ventures, strategic partnerships and alliances;
- our contractual relationships with our consolidated variable interest entities;
- existing competition and new market entrants;
- the introduction of synthetic alternatives to cannabis products by pharmaceutical and other companies;
- the immaturity of the cannabis industry and limited comparable, competitive and established industry best practices;
- the availability of and our reliance on third-party suppliers, service providers, contractors and manufacturers;
- wholesale and retail price fluctuations;
- public opinion and perception of the cannabis industry;
- the availability of raw or other materials;
- rising or volatile energy costs;
- agricultural and environmental risks and the impacts of environmental regulations on the cannabis industry and environmental protections;
- · physical security risks, such as theft;
- potential scrutiny from Canadian authorities;
- disparate state-by-state regulatory landscapes and licensing regimes for medical and adult-use cannabis;
- the difficulties cannabis businesses face accessing and maintaining banking or financial services due to federal regulations;
- · the cost and difficulty of complying with various regulatory schemes;
- the impact of state social equity legislation as it relates to the cannabis industry;
- the risk of high bonding and insurance costs;
- environmental regulations;
- effects of changes in laws and policies governing employees and by union organizing activity;
- potential divestment of licenses if required by regulatory authorities;
- · our dependency on the banking industry;
- required public disclosure and governmental filings containing personal information of our officers, investors and other stakeholders;
- potential findings by regulatory authorities that one of shareholders is unsuitable;
- the risk that our directors, officers, employees or investors are barred from entering the U.S.;
- the ability to, and constraints on, promoting and marketing cannabis products;
- potential U.S. Food and Drug Administration governance of the cannabis industry;
- the potential limitations on our ability to enforce our contracts or any liens granted to us;
- the potential lack of access to federal bankruptcy protections in the U.S.;
- reliance on information technology systems, the potential disclosure of personal information of patients and customers and cybersecurity risks;
- our reliance on third-party software providers;
- cost related to preserving our brand identity;
- our ability to protect our intellectual property due to limited intellectual property protection available for cannabis products and the potential infringement by third parties;
- potential infringement or misappropriation claims;
- the risk of receiving no return on our securities;
- our elimination of monetary liability and indemnification rights against our directors, officers and employees under British Columbia law;
- our dual class capital structure with Class A subordinate voting shares and Class B proportionate voting shares;
- the time and resources necessary to comply with corporate governance practices and securities rules and regulations in the U.S. and Canada;
- our management's ability to maintain effective internal controls;

Table of Contents

- our remediation plan and ability to remediate the material weaknesses in our internal controls over financial reporting;
- potential dilution if we issue additional Subordinate Voting Shares or Proportionate Voting Shares;
- market perception of sales of a substantial amount of Subordinate Voting Shares;
- · transfer restrictions on our Subordinate Voting Shares;
- price volatility of our Subordinate Voting Shares;
- our shareholders' limited participation in our affairs;
- our expectation to not declare or pay out dividends;
- the concentration of our voting control;
- the taxation of cannabis companies in the U.S., including the impact of Section 280E of the Internal Revenue Code of 1986, as amended; and
- other risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on March 15, 2024, as more particularly described under the heading "Item 1A. Risk Factors" therein.

Although we believe that the expectations and assumptions on which forward-looking statements are based are reasonable at the time made, undue reliance should not be placed on the forward-looking statements, because no assurance can be given that they will prove to be correct. Forward-looking statements address future events and conditions, and thus involve inherent risks and uncertainties. Readers are cautioned that the above list of cautionary statements is not exhaustive.

The cannabis industry involves risks and uncertainties that are subject to change based on various factors. Certain forward-looking statements contained herein concerning the cannabis industry and our general expectations concerning the cannabis industry are based on estimates prepared by us using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the cannabis industry. Such data is inherently imprecise.

Consequently, all forward-looking statements made in this Form 10-Q and our other documents are qualified by such cautionary statements and there can be no assurance that the anticipated results or developments will actually be realized or, even if realized, that they will have the expected consequences to or effects on us. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under applicable securities legislation.

PART I - FINANCIAL INFORMATION

ITEM 1. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

VERANO HOLDINGS CORP. Condensed Consolidated Balance Sheets

(\$ in Thousands)

| | M | arch 31, 2024 | December 31, 2023 |
|--|-----------|------------------|----------------------|
| ASSETS | (Ui | naudited) | |
| Current Assets: | | | |
| Cash and Cash Equivalents | \$ | 193,799 \$ | 174,760 |
| Accounts Receivable, net | | 41,926 | 38,981 |
| Held for Sale Assets | | 1,670 | 1,955 |
| Inventory | | 166,175 | 155,768 |
| Prepaid Expenses and Other Current Assets | | 15,209 | 22,732 |
| Total Current Assets | | 418,779 | 394,196 |
| Property, Plant and Equipment, net | | 499,142 | 501,304 |
| Right of Use Assets, net | | 91,949 | 93,459 |
| Intangible Assets, net | | 1,063,359 | 1,086,146 |
| Goodwill | | 231,291 | 231,291 |
| Deposits and Other Assets | | 10,500 | 12,349 |
| TOTAL ASSETS | <u>\$</u> | 2,315,020 \$ | 2,318,745 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | |
| LIABILITIES | | | |
| Current Liabilities: | | | |
| Accounts Payable | \$ | 28,310 \$ | 31,281 |
| Accrued Liabilities | | 61,302 | 66,766 |
| Income Tax Payable | | 258,067 | 248,471 |
| Current Portion of Lease Liabilities | | 9,889 | 9,750 |
| Current Portion of Debt | | 53,412 | 52,005 |
| Acquisition Consideration Payable | | 3,995 | 3,915 |
| Total Current Liabilities | | 414,975 | 412,188 |
| Long-Term Liabilities: | | | |
| Debt, net of Current Portion | | 391,274 | 393,637 |
| Lease Liabilities, net of Current Portion | | 86,368 | 87,397 |
| Deferred Income Taxes | | 180,250 | 182,215 |
| Other Long-Term Liabilities | | 3,237 | 3,228 |
| Total Long-Term Liabilities | | 661,129 | 666,477 |
| TOTAL LIABILITIES | \$ | 1,076,104 \$ | 1,078,665 |
| SHAREHOLDERS' EQUITY | | 1,238,916 | 1,240,080 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | \$ | 2,315,020 \$ | 2,318,745 |

Unaudited Interim Condensed Consolidated Statements of Operations

(\$ in Thousands except shares and per share amounts)

For the Three Months Ended March 31, 2024 2023 \$ 221,306 \$ Revenues, net of Discounts 227,060 Cost of Goods Sold, net 108,346 117,875 **Gross Profit** 112,960 109,185 Selling, General, and Administrative Expenses 90,289 75,243 Loss from Investments in Associates (160)**Income from Operations** 22,671 33,782 Other Income (Expense): Gain (Loss) on Disposal of Property, Plant and Equipment 67 (143)Loss on Debt Extinguishment (663)Interest Expense, net (15,114)(15,906)Other Income (Expense), net 1,803 (759)(14,699)Total Other Income (Expense), net (16,016)**Income Before Provision for Income Taxes and Non-Controlling Interest** 6,655 19,083 **Provision For Income Taxes** (11,477)(28,320)**Net Loss Before Non-Controlling Interest** (4,822)(9,237)Net Income Attributable to Non-Controlling Interest (4,822) \$ (9,237)Net Loss Attributable to Verano Holdings Corp. & Subsidiaries (0.03)Net Loss per share - basic & diluted (0.01)Basic & Diluted - weighted average shares outstanding 344,083,000 341,478,860

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity

(\$ in Thousands)

| | Subordinate Voting Shares (as converted) | Share Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Earnings (Deficit) | Non-Controlling Interest | Total |
|--|---|-------------------------|---|-----------------------------------|-----------------------------|--------------------------|
| Balance as of January 1, 2023 | 339,983,374 | \$ 1,665,957 | \$ (8) | \$ (324,399) | \$ | \$ 1,341,550 |
| Share-based compensation | 117,948 | 506 | _ | _ | _ | 506 |
| Issuance of shares to relieve liability obligations, net | 603,396 | 3,653 | _ | _ | _ | 3,653 |
| Foreign Currency Translation Adjustment | _ | _ | (1) | _ | _ | (1) |
| Contingent consideration & other adjustments to purchase accounting | 1,625,546 | _ | _ | _ | _ | _ |
| Net Loss | | | | (9,237) | | (9,237) |
| Balance as of March 31, 2023 | 342,330,264 | \$ 1,670,116 | \$ (9) | \$ (333,636) | <u>\$</u> | \$ 1,336,471 |
| | | | | | | |
| | Subordinate Voting Shares (as converted) | Share Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Earnings (Deficit) | Non-Controlling Interest | Total |
| Balance as of January 1, 2024 | Shares | \$ | Comprehensive Income (Loss) | Earnings (Deficit) | Interest | \$ Total 1,240,080 |
| Balance as of January 1, 2024 Share-based compensation | Shares (as converted) | \$ Capital | Comprehensive Income (Loss) | Earnings (Deficit) | Interest | \$ |
| | Shares (as converted) 344,074,096 | \$ Capital 1,681,840 | Comprehensive Income (Loss) | Earnings (Deficit) | Interest | \$ 1,240,080 |
| Share-based compensation Issuance of shares to relieve liability obligations, | Shares (as converted) 344,074,096 | \$ Capital 1,681,840 | Comprehensive Income (Loss) | Earnings (Deficit) | Interest | \$ 1,240,080 |
| Share-based compensation Issuance of shares to relieve liability obligations, net | Shares (as converted) 344,074,096 | \$ Capital 1,681,840 | Comprehensive Income (Loss) \$ (13) | Earnings (Deficit) | Interest | \$ 1,240,080 3,643 |
| Share-based compensation Issuance of shares to relieve liability obligations, net Foreign Currency Translation Adjustment Contingent consideration & other adjustments to | Shares (as converted) 344,074,096 57,872 — — | \$ Capital 1,681,840 | Comprehensive Income (Loss) \$ (13) | Earnings (Deficit) | Interest | \$ 1,240,080 3,643 |

Unaudited Interim Condensed Consolidated Statements of Cash Flows

(\$ in Thousands)

| Non-cash interest expense 112 55 (Gain) Loss on disposal of property, plant and equipment 143 66 Loss on debet cirtinguishment — 66 Untrealized (gain) loss on marketable securities (693) 22 Decrease in fair value of contingent consideration 3.928 55 Stock based compensation 3.928 55 Other, net 1,778 1,15 Changes in operating assets and liabilities: 1,778 1,15 Accounts payable (3,332) (1,67 Income tax payable (4,051) (1,31) Income tax payable (4,051) (1,01) Other assets, net (10,202) (5,18) NET CASH PROVIDED BY OPERATING ACTIVITIES 31,01 16,86 CASH FLOW FROM INVESTING ACTIVITIES (9,69) (8,55) Proceeds from disposal of assets — 1,81 NET CASH USED IN INVESTING ACTIVITIES (9,69) (6,72) CASH FLOW FROM FNANCING ACTIVITIES (9,69) (6,72) Proceeds from disposal of assets — 2,31 | | | hs Ended | ded March 31, | |
|---|---|---|----------|---------------|--|
| Net meome (loes) attributable to Verano Holdings Corp. and Subsidiances \$ (4,822) \$ (9,23) Adjustments to reconcile net loss to net cash provided by operating activities: 35,552 \$ 5,562 \$ 5,552 \$ 5,06 Right of use assets amortization 2,934 2,06 \$ 2,00 \$ 2,00 \$ 2,00 \$ 3,00 \$ 2,00 \$ 3,00 \$ 3,00 \$ 6,00 \$ 2,00 \$ 3,00 \$ 6,00 | | 2024 | | 2023 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: 35.552 35.052 35.052 35.052 35.052 35.052 36.052 | | | | (0 - | |
| Depreciation and amortization 35,552 35,05 Right of use assets amoritation 2,94 2,66 (Gain) Loss on disposal of property, plant and equipment 113 66 Loss on debt extinguishment — 66 Unrealized (gain) loss on marketable securities (693) 22 Decrease in fair value of contingent consideration — 1,26 Stock based compensation 3,228 5 Other, not 1,778 1,15 Changes in operating assets and liabilities (63,232) (1,67 Accounts receivable (3,232) (1,67 Inventory (9,998) 10,88 Accounts payable (4,031) (1,31) Income tax payable (4,031) (1,01) Other assets, net (10,065) 1,00 Other inhibities, net (10,292) (5,18 NET CASH PROWINCED BY OPERATING ACTIVITIES 3,041 16,82 CASH FLOW FROM INVESTING ACTIVITIES 9,699 (8,55 Proceeds from disposal of assets — 1,83 Acquistion of bu | | \$ (4,8 | 22) \$ | (9,237 | |
| Right of use assets amortization 2,94 2,66 Non-assi interest expense 112 2,56 Non-assi interest expense 113 66 (Gain) Loss on debt extinguishment — 66 Unrealized (gain) loss on marketable securities — 3,24 Decrease in fair value of contingent consideration — 3,24 Slock based compensation 1,78 1,15 Other, net 1,78 1,15 Changes in operating assets and liabilities — 1,232 1,65 Accounts receivable (3,23) 1,63 | | | | | |
| Non-eash interest expense 112 55 (Gain) Loss on disposal of property, plant and equipment 143 66 Loss on debt civinguishment — 66 66 Unrealized (gain) loss on marketable securities (693) 22 Decrease in fair value of contingent consideration 3.928 58 Stock based compensation 3.928 58 Other, net 1,778 1,15 Changes in operating assets and liabilities: 1,178 1,15 Accounts receivable (3,232) (1,67 Inventory (9,989) 10,88 Accounts payable (9,998) 10,88 Other assets, net (10,025) (5,18) Other assets, net (10,292) (5,18) NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,88 NET CASH PROVIDED BY OPERATING ACTIVITIES 9,099 (6,72) CASH FLOW FROM INNESTING ACTIVITIES 9,699 (6,72) NET CASH USED IN INVESTING ACTIVITIES 2,00 (6,72) Proceeds from disposal of assets 9 (3,90) (6,72) | | · | | | |
| (Gain) Loss on disposal of property, plant and equipment 143 66 Loss on debt extringuishment 66 66 Unrealized gain Joss on marketable securities (603) 22 Decrease in fair value of contingent consideration 3,28 56 Stock based compensation 1,778 1,158 Other, net 1,778 1,158 Changes in operating assets and liabilities 2,232 (1,67 Inventory (9,988) 10,88 Accounts payable (4,031) (11,31 Income tax, payable (4,031) (10,31 Other assets, net 10,065 1,00 Other inabilities, net 10,065 1,00 Other Inabilities, net 10,020 (5,18 NET CASH PROVIDED BY OPERATING ACTIVITIES 3,104 16,80 CASH FLOW FROM INVESTING ACTIVITIES (9,699) (8,55 Preceds from disposal of assets 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES 2,05 (5,00 < | - | · | | 2,609 | |
| Loss on debt extinguishment | • | | | 593 | |
| Unrealized (gain) loss on marketable securities | | | 43 | (67 | |
| Decrease in finir value of contingent consideration 3,928 5,80 Stock based compensation 3,928 5,80 Other, net 1,778 1,35 Changes in operating assets and liabilities: 3,232 1,67 Accounts receivable (3,232) 1,68 Inwentory (9,998) 10,88 Accounts payable (40,31) (1,131) Income tax payable 9,597 (5,01) Other assets, net 10,065 1,02 Other Inabilities, net (10,292) (5,18 NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES 9,699 (8,55 Proceeds from disposal of assets 9,699 (8,55 NET CASH USED IN INVESTING ACTIVITIES 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES 1,00 1,00 1,00 Proceeds from issuance of debt 2,150 (2,27) 1,00 1,00 1,00 1,00 1,00 1,00 | | | _ | 663 | |
| Stock based compensation 3,928 54 Other, net 1,778 1,15 Changes in operating assets and liabilities: 3,232 (1,67 Accounts receivable (3,232) (1,67 Inventory (9,998) (0,88 Accounts payable (4,031) (11,31 Income tax payable (9,597) (5,01 Other assets, net (10,065) 1,00 Other liabilities, net (10,292) (5,18 NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES (9,699) (8,55 Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES — 2,34 NET CASH USED IN INVESTING ACTIVITIES \$ (32) 5 (5) CASH FLOW FROM FINANCING ACTIVITIES — 2,37 Proceeds from issuance of debt — 2,37 Principal repayments of debt — 2,36 Debt issuance costs paid — | | (6 | 93) | 256 | |
| Other, net 1,778 1,158 Changes in operating assets and liabilities: 3,232 (1,67 Accounts receivable (3,232) (1,67 Inventory (9,998) 10,88 Accounts payable (9,997) (5,01 Other assets, net 10,065 1,0 Other liabilities, net (10,292) (5,18 NET CASH PROVIDE DRY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES 9,699 (8,55 Purchase of property, plant and equipment (9,699) (8,55 NET CASH USED IN INVESTING ACTIVITIES 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES 9,699 (6,72 CASH FLOW FROM FINANCING ACTIVITIES 3 (2 (5,00 Proceeds from issuance of debt - 23,71 (5,00 Proceeds from issuance of debt - 2,00 (3,00 (3,00 (3,00 (3,00 (3,00 (3,00 (3,00 (3,00 (3,00 (3,00 | | | _ | | |
| Accounts receivable | | • | | 544 | |
| Accounts receivable (3,232) (1,67) Inventory (9,998) 10,88 Accounts payable (4,031) (11,31) Income tax payable 9,597 (5,00) Other assets, net 10,065 1,00 Other liabilities, net (10,292) (5,188) NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,80 CASH FLOW FROM INVESTING ACTIVITIES Purchases of property, plant and equipment (9,699) (8,55 Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES S (32) 5 5 Proceeds from disposal of assets — 2,371 6 7 2,371 Proceeds from disposal of assets — 2,399 (6,72 6 7 2,371 6 7 2,371 6 7 2,371 6 7 2,371 6 6 7 2,371 6 6 7 2,371 | | 1,7 | 78 | 1,193 | |
| Inventory | | | | | |
| Accounts payable (4,031) (11,31) Income tax payable 9,597 (5,01) Other assets, net (10,065) 1,005 Other Inshiftes 31,041 16,86 NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES 8,55 16,80 Proceeds from disposal of assets - 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES 3 (30) (5,00) Proceeds from issuance of debt - 23,71 (5,00) (22,75) Principal repayments of debt (2,150) (22,75) (23,71) (22,75) (23,71 | | | | (1,670 | |
| Income tax payable | · | | | 10,885 | |
| Other assets, net 10,065 1,02 Other liabilities, net (10,292) (5,18 NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES Purchases of property, plant and equipment (9,699) (8,55 Proceeds from disposal of assets — 1,81 NET CASH USED IN INVESTING ACTIVITIES 9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES 9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES \$ (32) \$ Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,78 Debt issuance costs paid — 23,71 Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (136) — NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 10,27 CASH AND CASH EQUIVALENTS, | | • | | (11,316 | |
| Other liabilities, net (10,292) (5,184) NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES Well as a second of property, plant and equipment (9,699) (8,55) Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72) CASH FLOW FROM FINANCING ACTIVITIES S (32) 5 (50 Proceeds from issuance of debt — 2,37 7 (50 Proceeds from issuance of debt — 2,37 7 23,71 7 23,71 1 23,71 1 23,71 1 23,71 <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td>(5,018</td> | | · · · · · · · · · · · · · · · · · · · | | (5,018 | |
| NET CASH PROVIDED BY OPERATING ACTIVITIES 31,041 16,86 CASH FLOW FROM INVESTING ACTIVITIES Purchases of property, plant and equipment (9,699) (8,55 Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES S (32) \$ (50 Proceeds from issuance of debt — 23,71 \$ (50 \$ (22,75) \$ (22,75) \$ (22,75) \$ (22,75) \$ (22,75) \$ (23,70) \$ | | | | 1,023 | |
| CASH FLOW FROM INVESTING ACTIVITIES Purchases of property, plant and equipment (9,699) (8,55 Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES S (32) \$ (50 Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75) Debt issuance costs paid — (30 Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | Other liabilities, net | (10,2 | .92) | (5,186 | |
| Proceeds from disposal of assets — 1,83 NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES Requisition of business, net of cash acquired \$ (32) \$ (50) Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75) Debt issuance costs paid — (30) Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | | (0.4 | (00) | (0.555 | |
| NET CASH USED IN INVESTING ACTIVITIES (9,699) (6,72 CASH FLOW FROM FINANCING ACTIVITIES Acquisition of business, net of cash acquired \$ (32) \$ (50) Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75) Debt issuance costs paid — (30) Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, EEGINNING OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | | (9,0 | 99) | . , | |
| CASH FLOW FROM FINANCING ACTIVITIES Acquisition of business, net of cash acquired \$ (32) \$ (50) Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75 Debt issuance costs paid — (30) Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | - | | | | |
| Acquisition of business, net of cash acquired \$ (32) \$ (50) Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75) Debt issuance costs paid — (30) Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | NET CASH USED IN INVESTING ACTIVITIES | (9,6 | 99) | (6,/25 | |
| Proceeds from issuance of debt — 23,71 Principal repayments of debt (2,150) (22,75 Debt issuance costs paid — (30 Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Principal repayments of debt (2,150) (22,75 Debt issuance costs paid — (30 Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (2,318) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION \$ 15,002 \$ 15,31 | Acquisition of business, net of cash acquired | \$ | 32) \$ | (500 | |
| Debt issuance costs paid — (30 Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | Proceeds from issuance of debt | | _ | 23,710 | |
| Other financing activities (136) — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | Principal repayments of debt | (2,1 | 50) | (22,759 | |
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (2,318) 14 NET INCREASE IN CASH AND CASH EQUIVALENTS \$ 19,024 \$ 10,27 Effects of exchange rate fluctuations on cash and cash equivalents \$ 15 \$ (CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | Debt issuance costs paid | | _ | (309 | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS Effects of exchange rate fluctuations on cash and cash equivalents CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | Other financing activities | (1 | 36) | _ | |
| Effects of exchange rate fluctuations on cash and cash equivalents CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | (2,3 | 18) | 142 | |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | NET INCREASE IN CASH AND CASH EQUIVALENTS | \$ 19,0 |)24 \$ | 10,279 | |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD \$ 174,760 \$ 84,85 CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | | | | | |
| CASH AND CASH EQUIVALENTS, END OF PERIOD \$ 193,799 \$ 95,12 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | · | | | (1 | |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest paid, net \$ 15,002 \$ 15,31 | CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | \$ 174,7 | 60 \$ | 84,851 | |
| Interest paid, net \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ | CASH AND CASH EQUIVALENTS, END OF PERIOD | \$ 193, | 99 \$ | 95,129 | |
| | SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
| | Interest paid, net | \$ 15,0 | 002 \$ | 15,313 | |
| | | | | 3,653 | |

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION

(a) Description of Business

Unless otherwise stated or the context requires otherwise, references herein to the "Company," "Verano," "we," "us," and "our" mean Verano Holdings Corp. and its direct and indirect subsidiaries, and controlled and managed entities.

The Company is a vertically integrated cannabis operator that focuses on limited-licensed markets in the United States ("U.S."). As a vertically integrated operator, the Company owns, operates, manages, controls, and/or has licensing, consulting or other commercial agreements with cultivation, processing, and retail licenses across 13 state markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia).

The Company also conducts pre-licensing activities in other markets. In these markets, the Company has either applied for licenses, or plans on applying for licenses, but does not currently own or manage any cultivation, processing, or retail licenses.

The Company's Class A subordinate voting shares, no par value (the "Subordinate Voting Shares") are listed on Cboe Canada ("Cboe") under the ticker symbol "VRNO" and are quoted in the United States on the OTCQX marketplace operated by the OTC Market Group, under the ticker symbol "VRNOF".

The Company's corporate headquarters is located at 224 W Hill Street, Suite 400, Chicago, Illinois 60610.

(b) Basis of Presentation

The accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Unless otherwise indicated, all references to "\$" or "US\$" in this Form 10-Q refer to United States dollars, and all references to "C\$" refer to Canadian dollars. These Unaudited Interim Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2023 (the "2023 Annual Audited Financials"), included in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2024 (the "Form 10-K"). Certain prior year amounts have been reclassified to conform to the current year's presentation, which the Company does not consider to be material. The accompanying Unaudited Interim Condensed Consolidated Financial Statements include the accounts of Verano Holdings Corp. and its direct and indirect subsidiaries as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification ("ASC") 810 Consolidation. The preparation of the Company's Unaudited Interim Condensed Consolidated Financial Statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of assets and liabilities in such financial statements and in the accompanying notes. Actual results may differ materially from these estimates. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the 2024 full year or any future periods. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated balance sheet as of December 31, 2023 contained in the 2023 Annual Audited Financials included in the Form 10-K.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION (Continued)

(c) Basis of Consolidation

The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with ASC 810 *Consolidation*. All transactions and balances between these entities have been eliminated upon consolidation.

(d) Significant Accounting Policies

There have been no changes to the Company's significant accounting policies as described in *Note 2 - Significant Accounting Policies* to the 2023 Annual Audited Financials included in the Form 10-K.

(e) Earnings (Loss) per Share

Basic earnings (loss) per share is calculated using the treasury stock method, by dividing the net earnings (losses) attributable to shareholders by the weighted average number of shares (including the Company's Class B proportionate voting shares, no par value (the "Proportionate Voting Shares") on an as converted to Subordinate Voting Shares basis of 100 Subordinate Voting Shares to one Proportionate Voting Share) outstanding during each of the periods presented. Contingently issuable shares (including shares held in escrow) are not considered outstanding shares and consequently are not included in the earnings (loss) per share calculations. Diluted income per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares.

To determine diluted income per share, the Company assumes that any proceeds from the exercise of dilutive share options would be used to repurchase shares at the average market price during the period. The diluted income per share calculation excludes any potential conversion of share options and convertible debt, if any, that would increase earnings per share or decrease loss per share. No potentially dilutive share equivalents were included in the computation of diluted loss per share for the three months ended March 31, 2024 and 2023 because their impact would have been anti-dilutive.

(f) Recently Issued Accounting Standards

In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update 2023-07 - ASC 280 Segment Reporting - Improvements to Reportable Segment Disclosures ("ASC 280"), which extends the existing requirements for annual disclosures to quarterly periods, and requires that both annual and quarterly disclosures present segment expenses using line items consistent with information regularly provided to the chief operating decision maker. ASU 280 is effective for annual periods beginning after December 15, 2023 and quarterly periods beginning after December 15, 2024. The Company does not expect implementation of the new disclosure guidance to have a material impact to its consolidated financial statements.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

2. INVENTORY

The Company's inventory consists of the following as of March 31, 2024 and December 31, 2023:

| | March 31, 2024 | December 31, 2023 |
|-----------------------------|-------------------|----------------------|
| Raw Materials | \$ 3,573 | \$ 5,336 |
| Work in Process | 121,508 | 114,620 |
| Packaging and Miscellaneous | 8,327 | 7,899 |
| Finished Goods | 32,767 | 27,913 |
| | | |
| Total Inventory | \$ 166,175 | \$ 155,768 |

During the year ended December 31, 2023, the Company classified Packaging and Miscellaneous as a component of Prepaid Expenses and Other Current Assets on the Consolidated Balance Sheets as of December 31, 2023. Packaging and Miscellaneous has been reclassified to Inventory in the Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2024, to better reflect the character of the underlying assets. Prior periods have been reclassified to conform to the current period presentation.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

3. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment and related accumulated depreciation consists of the following as of March 31, 2024 and December 31, 2023:

| | I | March 31, 2024 | De | ecember 31, 2023 |
|--|----|-------------------|----|---------------------|
| Land | \$ | 30,934 | \$ | 30,934 |
| Buildings and Improvements | | 194,274 | | 194,274 |
| Furniture and Fixtures | | 20,031 | | 19,884 |
| Computer Equipment and Software | | 26,912 | | 25,861 |
| Leasehold Improvements | | 232,904 | | 230,877 |
| Tools and Equipment | | 90,374 | | 90,386 |
| Vehicles | | 4,390 | | 4,373 |
| Assets Under Construction (1) | | 47,204 | | 39,844 |
| | | | | |
| Total Property, Plant and Equipment, Gross | | 647,023 | | 636,433 |
| Less: Accumulated Depreciation | | (147,881) | | (135,129) |
| | | | | |
| Total Property, Plant and Equipment, Net | \$ | 499,142 | \$ | 501,304 |

⁽¹⁾ Assets under construction represent construction in progress related to facilities not yet completed or otherwise not placed in service.

For the three months ended March 31, 2024 and March 31, 2023, depreciation expense included in costs of goods sold totaled \$8,724 and \$8,524, respectively. For the three months ended March 31, 2024 and March 31, 2023, depreciation expense included in selling, general, and administrative expense totaled \$4,041 and \$3,667, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

4. INTANGIBLE ASSETS AND GOODWILL

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value as of the acquisition date. Amortization of definite life intangible assets is provided on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods for intangible assets are reviewed by the Company at each year end, and any changes in estimates are accounted for prospectively.

As of March 31, 2024, intangible assets consisted of the following:

| | Licenses | 7 | Tradenames | Technology | Total |
|-------------------------------|-----------------|----|------------|-------------|-----------------|
| Cost | | | | | |
| Balance as of January 1, 2024 | \$ 1,269,326 | \$ | 54,166 | \$ 6,431 | \$ 1,329,923 |
| Balance as of March 31, 2024 | \$ 1,269,326 | \$ | 54,166 | \$ 6,431 | \$ 1,329,923 |
| | | | | | |
| Accumulated Amortization | | | | | |
| Balance as of January 1, 2024 | 225,751 | | 15,001 | 3,025 | 243,777 |
| Amortization | 21,173 | | 1,355 | 259 | 22,787 |
| Balance as of March 31, 2024 | \$ 246,924 | \$ | 16,356 | \$ 3,284 | \$ 266,564 |
| | | | | | |
| Net Book Value | | | | | |
| Balance as of January 1, 2024 | 1,043,575 | | 39,165 | 3,406 | 1,086,146 |
| Balance as of March 31, 2024 | \$ 1,022,402 | \$ | 37,810 | \$ 3,147 | \$ 1,063,359 |
| | | | | | |

The following table outlines the estimated annual amortization expense related to intangible assets as of March 31, 2024:

| Year Ending December 31, | Estimate Amortizat | |
|--------------------------|-----------------------|-------|
| 2024 (Remaining) | \$ 68 | 8,361 |
| 2025 | 91 | 1,149 |
| 2026 | 90 | 0,434 |
| 2027 | 90 | 0,360 |
| 2028 | 90 | 0,342 |
| Thereafter | 632 | 2,713 |
| Total | \$ 1,063 | 3,359 |

The changes in the carrying amount of goodwill, by reportable segment, for the three months ended March 31, 2024 were as follows:

| | Janu | uary 1, 2024 | Adjustments to purchase price 2024 Impairment allocation Acquisition | | | | | | Ma | arch 31, 2024 |
|-------------|------|--------------|--|---|----|---|----|---|----|---------------|
| Cultivation | \$ | 49,318 | \$ | _ | \$ | | \$ | | \$ | 49,318 |
| Retail | | 181,973 | | _ | | _ | | _ | | 181,973 |
| Total | \$ | 231,291 | \$ | | \$ | | \$ | _ | \$ | 231,291 |

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

5. EARNINGS (LOSSES) PER SHARE

The Company presents basic earnings (losses) per share. Basic earnings (losses) per share is calculated by dividing the earnings (loss) attributable to shareholders by the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding during the periods presented. Diluted earnings (losses) per share is computed based on the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding, to the extent dilutive.

The computations of net earnings (loss) per share on a basic and diluted basis, including reconciliations of the numerators and denominators, for the three months ended March 31, 2024 and March 31, 2023 were as follows:

East 4h a Thura Mantha Endad Manah 21

| | For the Three Months Ended March 31, | | | | | |
|--|--------------------------------------|-------------|----|-------------|--|--|
| | · | 2024 | | 2023 | | |
| Numerator | | | | | | |
| Net Loss attributable to Verano Holdings Corp. | \$ | (4,822) | \$ | (9,237) | | |
| Denominator | | | | | | |
| <u>Basic</u> | | | | | | |
| Weighted-average shares outstanding – basic | | 344,083,000 | | 341,478,860 | | |
| <u>Diluted</u> | | | | | | |
| Weighted-average shares outstanding – diluted | | 344,083,000 | | 341,478,860 | | |
| Net Loss per share - basic & diluted | | (0.01) | | (0.03) | | |
| | | | | | | |

Potentially dilutive securities of approximately 4,580,744 and 365,774 for the three months ended March 31, 2024 and March 31, 2023, respectively, were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

6. TRANSACTIONS

Business Combinations

The Company has determined that the acquisitions described below are business combinations under ASC Topic 805, *Business Combinations*. Acquisitions that are determined to be the acquisition of a business are accounted for by applying the acquisition method, whereby the assets acquired, and the liabilities assumed are recorded at their fair values at the date of acquisition with any excess of the aggregate consideration over the fair values of the identifiable net assets allocated to goodwill. Operating results for the companies acquired have been included in these Unaudited Interim Condensed Consolidated Financial Statements from the date of the acquisition. Any goodwill recognized is attributed based on reporting units.

The purchase price allocations for the acquisitions reflect various fair value estimates and analyses which are subject to change within the measurement period, which is the one-year period subsequent to the acquisition date. The primary areas of the purchase price allocation that are subject to change relate to the fair value of certain tangible assets, the value of intangible assets acquired, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair value of the net assets acquired at the acquisition date during the measurement period.

Measurement period adjustments that the Company determined to be material will be applied prospectively in the Company's future consolidated financial statements, and depending on the nature of the adjustments, other periods subsequent to the period of acquisition could be affected.

WSCC, Inc.

On July 6, 2021, Verano entered into a merger agreement to acquire 100% of the equity interests of WSCC, Inc ("Sierra Well"). Sierra Well held cannabis licenses that allow it to cultivate, produce and sell medical and recreational cannabis products in the state of Nevada, including sales through its retail dispensaries located in Carson City and Reno. The transaction closed on September 7, 2022.

During the quarter ended March 31, 2024, the Company paid cash consideration of \$32 and issued 31,181 Subordinate Voting Shares to the former shareholders of Sierra Well, which had been held back to secure indemnification obligations of such shareholders. As of March 31, 2024, all consideration related to the acquisition has been paid.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. DEBT

As of March 31, 2024 and December 31, 2023 debt consisted of the following:

| | March 31, 2024 | | December 31, 2023 |
|---------------------------------|-------------------|----|----------------------|
| Credit Facility | \$ 347,900 | \$ | 348,950 |
| Secured Promissory Notes | 1,567 | | 1,582 |
| Mortgage Loans | 110,257 | | 111,221 |
| Vehicle and Equipment Loans | 961 | | 1,081 |
| Unamortized Debt Issuance Costs | (15,999) | | (17,192) |
| | | | |
| Total Debt | \$ 444,686 | \$ | 445,642 |
| | | | |
| Less: Current Portion of Debt | 53,412 | _ | 52,005 |
| | | | |
| Total Long-Term Debt, net | \$ 391,274 | \$ | 393,637 |

Credit Facility

On October 27, 2022, Verano and certain of its subsidiaries and affiliates from time-to-time party thereto (collectively, the "Borrowers"), entered into a Credit Agreement (the "2022 Credit Agreement") with Chicago Atlantic Admin, LLC, as administrative agent for the lenders, and the lenders from time-to-time party thereto, pursuant to which the lenders advanced the Borrowers a \$350,000 senior secured term loan, all of which was used to repay the principal indebtedness outstanding under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan in the aggregate principal amount of up to \$100,000; provided that the lenders elect to fund such incremental term loan. Beginning in October 2023, the loan requires scheduled amortization payments of \$350 per month and the remaining principal balance is due in full on October 30, 2026.

The 2022 Credit Agreement also provides the Borrowers with the right to (a) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (b) incur additional mortgage financing from third-party lenders secured by real estate acquired after the closing date, and (c) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 pursuant to a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, each of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions.

The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. **DEBT** (Continued)

At any time, the Company may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations and warranties and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Borrowers' ability to incur additional indebtedness and grant liens that are not otherwise permitted, and the ability to enter into or consummate acquisitions or dispositions that are not otherwise permitted, among others. Additionally, the 2022 Credit Agreement requires the Borrowers to meet certain financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of March 31, 2024, the Company was in compliance with such covenants.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL

Subordinate Voting Shares and Proportionate Voting Shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity. The proceeds from the exercise of stock options or warrants together with amounts previously recorded in reserves over the vesting periods are recorded as share capital. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with ASC 740, *Income Taxes*.

(a) Issued and Outstanding

As of March 31, 2024, the Company had 344,163,149 Subordinate Voting Shares issued and outstanding and no Proportionate Voting Shares outstanding. The Company has the following two classes of share capital, with each class having no par value:

(i) Subordinate Voting Shares

The holders of the Subordinate Voting Shares are entitled to receive dividends issued by the Company and one vote per share at shareholder meetings of the Company. All Subordinate Voting Shares are ranked equally regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Subordinate Voting Shares.

(ii) Proportionate Voting Shares

Each Proportionate Voting Share is convertible into 100 Subordinate Voting Shares. The holders of the Proportionate Voting Share are entitled to receive dividends issued by the Company on an as converted to Subordinate Voting Share basis and 100 votes per share at shareholder meetings of the Company. The Proportionate Voting Shares are ranked equally on an as converted to Subordinate Voting Share basis regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Proportionate Voting Shares.

(b) Stock-Based Compensation

In February 2021, the Company established the Verano Holdings Corp. Stock and Incentive Plan (the "Plan"), which provides for stock-based remuneration for its eligible directors, officers, employees, consultants, and advisors. The maximum number of restricted stock units ("RSUs"), options and other stock based awards that may be issued under the Plan cannot exceed 10% of the Company's then issued and outstanding share capital, determined on an as converted to Subordinate Voting Shares basis. All goods and services received in exchange for the grant of any stock-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods and services received, the Company measures their value indirectly by reference to the fair value of the equity instruments granted. Equity-settled stock-based payments under stock-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to equity.

The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. Estimates are subsequently revised if there is any indication that the number of shares expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized.

Option and RSU grants generally vest in installments over 12 to 30 months and options typically have a life of ten years.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL (Continued)

Options

The Company had 37,711 fully vested and exercisable options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, with a weighted average exercise price of C\$30.11 and a weighted average remaining contractual life of 6.86 years as of March 31, 2024.

1,245 fully vested options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, were cancelled during the three months ended March 31, 2024 due to termination of employment. No options were granted or forfeited during the three months ended March 31, 2024. As of March 31, 2024 and December 31, 2023, there were no in-the-money options.

RSUs

The following table summarizes the number of unvested RSU awards as of March 31, 2024 and December 31, 2023 and the changes during the three months ended March 31, 2024:

| | | Weighted Avg. Grant Date Fair |
|------------------------------------|---------------------|----------------------------------|
| | Number of Shares | Value C\$ |
| Unvested RSUs at December 31, 2023 | 8,812,537 | 4.72 |
| Granted | 77,575 | 8.00 |
| Forfeited | 173,100 | 4.52 |
| Vested | 58,214 | 11.83 |
| Unvested RSUs at March 31, 2024 | 8,658,798 | 4.72 |

The stock-based compensation expense for the three months ended March 31, 2024 and 2023 were as follows:

| | · | Three Months Ended March 31, | | | | | |
|---|----|------------------------------|--------|--|--|--|--|
| | - | 2024 | 2023 | | | | |
| Stock Options | \$ | _ \$ | \$ 76 | | | | |
| Restricted Stock Units | | 3,928 | 468 | | | | |
| Total Stock Based Compensation Expense | \$ | 3,928 | \$ 544 | | | | |

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

9. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three months ended March 31, 2024 and 2023:

| | Fo | For the Three Months Ended March 31, | | | | | |
|----------------------------|----|--------------------------------------|----------|--|--|--|--|
| | | 2024 | 2023 | | | | |
| Income before Income Taxes | \$ | 6,655 \$ | 19,083 | | | | |
| Income Tax Expense | | (11,477) | (28,320) | | | | |
| Effective Tax Rate | | 172 % | 148 % | | | | |

The effective tax rates for the three months ended March 31, 2024 and 2023 were based on the Company's forecasted annualized effective tax rates and were adjusted for discrete items that occurred within the periods presented. Net discrete tax items of \$(236) and \$4,847 were recorded during the three months ended March 31, 2024 and 2023, respectively. Discrete items recorded during the three months ended March 31, 2024 and 2023 primarily relate to penalties and interest on unpaid tax liabilities, impacts of prior period return to provision adjustments, remeasurement of deferred taxes for state tax rate changes, and book remeasurement adjustments not recognized for tax purposes.

Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code of 1986, as amended (the "Code") Section 280E, under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and the Company's effective tax rates are well in excess of statutory tax rates.

Taxes paid during the three months ended March 31, 2024 and 2023 were \$9,585 and \$36,394, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

10. LEASES

The Company has operating leases for some of its retail dispensaries and processing and production facilities located throughout the U.S., as well as for its corporate offices located in Chicago, Illinois. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date.

Leases with an initial term of 12 months or less are not recorded on the Company's balance sheet. Certain leases require payments for taxes, insurance, and maintenance, and are considered non-lease components. The Company accounts for non-lease components separately.

The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset.

The Company leases certain business facilities from third parties under non-cancellable operating lease agreements that contain minimum rental provisions that expire through 2037. Some leases also contain renewal provisions and provide for rent abatement and escalating payments.

During the three months ended March 31, 2024 and 2023, the Company recorded approximately \$4,999 and \$4,313 in operating lease expense, respectively, of which \$114 and \$206 was included in cost of goods sold for the same periods, respectively.

Other information related to operating leases as of and for the periods ended March 31, 2024 and December 31, 2023, were as follows:

| | March 31, 2024 | December 31, 2023 | | |
|---|----------------|--------------------------|--|--|
| Weighted average remaining lease term - years | 8.09 | 8.19 | | |
| Weighted average discount rate | 9.62 % | 9.52 % | | |

Maturities of lease liabilities for operating leases as of March 31, 2024 were as follows:

| Year Ending December 31, | Maturities of Lease Liability |
|----------------------------------|-------------------------------|
| 2024 (Remaining) | \$ 13,680 |
| 2025 | 18,099 |
| 2026 | 17,096 |
| 2027 | 16,435 |
| 2028 | 15,876 |
| Thereafter | 61,412 |
| | |
| Total Lease Payments | 142,598 |
| | |
| Less: Imputed Interest | (46,341) |
| | |
| Present Value of Lease Liability | \$ 96,257 |

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER

(a) Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 31, 2024, other than as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations. There are no proceedings in which the Company is a party and any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

On January 31, 2022, the Company entered into an Arrangement Agreement (the "GGH Arrangement Agreement") with Goodness Growth Holdings, Inc. ("GGH"), pursuant to which it agreed to acquire all of the issued and outstanding equity interests of GGH in exchange for equity interests in the Company, subject to the conditions set forth in the GGH Arrangement Agreement. On October 13, 2022, the Company provided written notice to GGH of GGH's breach of the GGH Arrangement Agreement and exercised the Company's termination rights under the GGH Arrangement Agreement. On October 21, 2022, GGH filed suit against the Company in the Supreme Court of British Columbia alleging that the Company breached (i) the GGH Arrangement Agreement through, among other things, the purported wrongful repudiation of the GGH Arrangement Agreement, (ii) the duty of good faith, and (iii) the duty of honest performance in contract. In addition, on November 14, 2022, the Company filed a counterclaim asserting that GGH owes it a termination fee in the amount of \$14,875, or alternatively, the reimbursement of out-of-pocket fees and expenses of up to \$3,000 as a result of our termination of the GGH Arrangement Agreement, which was based upon our belief that GGH breached covenants and representations in the GGH Arrangement Agreement and the occurrence of other termination events. GGH filed a response to such counterclaim on December 7, 2022, in which GGH denied it was obligated to pay any termination fee or transaction expenses. As of March 31, 2024, both the Company and GGH are engaged in ongoing discovery efforts. Please see *Note 17 - Subsequent Events* for an update on this matter. The Company can provide no guarantees or assurances that it will prevail or settle this lawsuit or its counterclaim on favorable terms, if at all, and an adverse outcome could have a material adverse effect on its business, results of operations and financial condition.

(b) Contingencies

During the first quarter of 2023, the Company discovered a potential liability related to a previous acquisition that was deemed to be both probable and estimable. Per ASC 450 *Contingencies*, when both of these criteria are present, a contingent liability should be recorded. Based on this, the Company recorded a corresponding charge in Other Income, net of \$1,893 for the three months ended March 31, 2023.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER (Continued)

(c) Illegality of Cannabis at the U.S. Federal Level

Verano operates within states where cannabis use, medical or adult use or both, has been approved by state and local regulatory bodies. Notwithstanding the permissive regulatory environment of medical, and in some cases also adult use cannabis at the state level, under U.S. federal law cannabis (other than hemp) is a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 811) (the "Controlled Substances Act") which means it is viewed by the U.S. federal government as a drug that has a high potential for abuse and no therapeutic value. Therefore, even in states or territories that have legalized cannabis to some extent, the cultivation, processing, distribution, possession and sale of cannabis violates the Controlled Substances Act. Moreover, individuals and entities may violate U.S. federal law if they aid and abet another in violating the Controlled Substances Act is also a predicate for other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities, civil forfeiture or divestiture.

Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its cannabis licenses in the U.S., the listing and trading of its securities on stock exchanges and platforms, its financial position, operating results, profitability, liquidity and the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time and resources could be substantial.

There can be no assurance that the comprehensive U.S. federal legislation that would de-schedule and de-criminalize cannabis will be passed in the near future or at all. If such legislation is passed, there is no guarantee that it will include provisions that preserve the current state-based cannabis programs under which the Company operates or that such legislation will otherwise be favorable to the Company and its business.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

12. SEGMENTS

The Company conducts and manages its business through two reportable segments, representing the major lines of its cannabis business: cultivation (wholesale) and retail. The cultivation (wholesale) segment consists of the cultivation, production and sale of cannabis products to retail stores. The retail segment consists of the retailing of cannabis to patients and consumers. Summarized financial information for these segments is as follows:

| | Fo | For the Three Months Ended March 31, | | | | | | |
|--|----|--------------------------------------|------|----------|--|--|--|--|
| | | 2024 | 2023 | | | | | |
| Revenue, net of Discounts | | | | | | | | |
| Cultivation (Wholesale) | \$ | 85,906 | \$ | 80,267 | | | | |
| Retail | | 168,588 | | 184,242 | | | | |
| Intersegment Eliminations | | (33,188) | | (37,449) | | | | |
| Total Revenue, net of Discounts | | 221,306 | | 227,060 | | | | |
| Gross Profit | | | | | | | | |
| Cultivation (Wholesale) | | 24,186 | | 10,824 | | | | |
| Retail | | 88,774 | | 98,361 | | | | |
| Total Gross Profit | | 112,960 | | 109,185 | | | | |
| Depreciation and Amortization | | | | | | | | |
| Cultivation (Wholesale) | | 19,088 | | 18,522 | | | | |
| Retail | | 16,464 | | 16,534 | | | | |
| Total Depreciation and Amortization | | 35,552 | | 35,056 | | | | |
| | | | | | | | | |
| Income taxes | | | | | | | | |
| Cultivation (Wholesale) | | 5,907 | | 10,257 | | | | |
| Retail | | 5,570 | | 18,063 | | | | |
| Total Income Taxes | | 11,477 | | 28,320 | | | | |

The following table reconciles gross profit to consolidated income before provision for income taxes.

| | 2024 | 2023 |
|---|----------|----------|
| Gross Profit | 112,960 | 109,185 |
| Selling, General, and Administrative Expenses | (90,289) | (75,243) |
| Loss from Investments in Associates | _ | (160) |
| Total Other Income (Expense), net | (16,016) | (14,699) |
| Income Before Provision for Income Taxes | 6,655 | 19,083 |

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

13. LOYALTY OBLIGATIONS

The Company has customer loyalty programs where retail customers accumulate points for each dollar of spending, net of tax. These points are recorded as a contractual liability until customers redeem their points for discounts on eligible products as part of an in-store sales transaction. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point obligation incurred.

The Company modified the loyalty program in 2022. The modified loyalty program has a calculated standalone selling price that ranges between \$0.03¹ and \$0.06¹ per loyalty point. Upon redemption, the loyalty program obligation is relieved, and the offset is recorded as revenue. The Company estimates that 20% of points will not be redeemed (breakage) prior to their six-month expiration dates. The Company continues to evaluate breakage and redemption values to determine the standalone selling price.

As of December 31, 2023, there were approximately 110,000,000¹ points outstanding with an approximate value of \$5,781. As of March 31, 2024, there were approximately 114,000,000¹ points outstanding with an approximate value of \$6,015. Such balances are included in accrued liabilities on the Company's Condensed Consolidated Balance Sheets.

¹ Such amount not in Thousands

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

14. CONSOLIDATION

In accordance with ASC 810, the Company consolidates through the variable interest entity ("VIE") model. The following table presents the summarized financial information about the Company's consolidated VIEs, which are included in the Company's Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.

| | March 31, 2024 | | December 31, 2023 |
|--|----------------|---------|--------------------------|
| Current Assets | \$ | 8,857 | \$ 14,671 |
| Non-Current Assets | | 26,730 | 28,568 |
| Current Liabilities | | 30,915 | 30,437 |
| Non-Current Liabilities | | 7,477 | 7,614 |
| Equity attributable to Verano Holdings Corp. | | (2,805) | 5,188 |

Consolidated Variable Interest Entities

Consolidated VIEs occur when (a) the Company closes an acquisition while the state has not finalized the transfer of the cannabis license or (b) the Company owns an equity interest in a joint venture, which it exercises control over.

Consolidation occurs on the effective date of the purchase agreement, or in the case of joint venture VIEs, on the effective date of a limited liability company agreement governing the applicable joint venture, and an MSA. The MSA grants the management company, Verano, the ability to make business operating decisions, manage and staff employees, determine product mix, and the authority to direct allocation of cash. The MSA or the limited liability company agreement also allows Verano to limit distributions of the entity at Verano's discretion. Certain states may limit the distribution or transfer of cash until license transfer.

The Company has entered into financing arrangements with certain VIEs to provide funding for potential capital expenditures including, but not limited to, the construction of dispensaries and other facilities.

The Company applies ASC 810-10-15 to determine control of the legal entity. With respect to VIEs acquired via acquisition, the purchase agreements limit the sellers involvement in future operations, and their risks of loss. With respect to joint venture VIEs, the limited liability company agreements limit the partners' involvement in future operations and control over financial decisions, including distributions. In addition, Verano enters into an MSA with the legal entity that grants the Company strategic decision-making ability of the business operations.

The Company is involved in all qualitative and quantitative aspects of each consolidated VIE, such as but not limited to, software choices, procurement, staffing and payroll, advertising, and use of cash flow. With respect to VIEs acquired via acquisition, the Company absorbs all risk of loss and receives expected future returns based on the purchase agreement and MSA, resulting in Verano being the primary beneficiary.

Verano does not fully own all entities consolidated under ASC 810 and records a non-controlling interest for such non-owned portion in the Unaudited Interim Condensed Consolidated Financial Statements. The income of less-than-wholly owned entities is attributed to non-controlling interest and Verano based on the contractual arrangements between the other interest holders and Verano, or, in the absence of contractual arrangements, on a pro rata basis based on relative ownership percentage. As an exception to the aforementioned attribution method, during periods in which a less-than-wholly owned entity records an accumulated deficit, the net losses of the less-than-wholly owned subsidiary are, generally, attributed entirely to Verano.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

15. FAIR VALUE MEASUREMENTS

The Company applies fair value accounting for all financial assets and liabilities that are recognized or disclosed at fair value in the Consolidated Financial Statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and credit-risk.

The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels, and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and
- Level 3 Inputs for the asset or liability that are not based on observable market data.

Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and acquisition consideration payable.

For the Company's long-term debt (which primarily consists of a credit facility and mortgage loans), for which there were no quoted market prices of active trading markets, it was not practicable to estimate the fair value of these financial instruments. The carrying amount of debt as of March 31, 2024 and December 31, 2023 was \$444,686 and \$445,642, which included \$53,412 and \$52,005, respectively, of short-term debt due within one year.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The fair value of the Company's financial instruments associated with each of the three levels of the hierarchy are:

| | As of March 31, 2024 | | | | | | |
|-----------------------------------|----------------------|----|---------|------------|----|---------|--|
| | Level 1 | | Level 2 | Level 3 | | Total | |
| Cash and Cash Equivalents | \$ 193,799 | \$ | | <u> </u> | \$ | 193,799 | |
| Investments | 2,988 | | _ | _ | | 2,988 | |
| Acquisition Consideration Payable | _ | | _ | (3,995) | | (3,995) | |
| Total | \$ 196,787 | \$ | _ | \$ (3,995) | \$ | 192,792 | |
| | | | | | | | |

| | As of December 31, 2023 | | | | | | | |
|-----------------------------------|-------------------------|---------|----|---------|----|---------|----|---------|
| | | Level 1 | | Level 2 | | Level 3 | | Total |
| Cash and Cash Equivalents | \$ | 174,760 | \$ | _ | \$ | _ | \$ | 174,760 |
| Investments | | 2,294 | | _ | | _ | | 2,294 |
| Acquisition Consideration Payable | | _ | | _ | | (3,915) | | (3,915) |
| Total | \$ | 177,054 | \$ | _ | \$ | (3,915) | \$ | 173,139 |

As of March 31, 2024, the Company held publicly traded shares of \$2,988 which is included in other assets in the accompanying Condensed Consolidated Balance Sheet, and is a Level 1 financial instrument.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

16. RELATED PARTY TRANSACTIONS

2022 Credit Agreement

George Archos, the Chairman, Chief Executive Officer and Founder of the Company, participated in the 2022 Credit Agreement as a lender funding \$1,000 of the \$350,000 principal amount. Mr. Archos is excluded from certain approval rights of the lenders and any penalties and fees due to Mr. Archos under the 2022 Credit Agreement are immaterial to the Company.

Two Pointo

In October 2022, the Company entered into a conditional management and services agreements with each of Americana Dream, LLC and Green Therapy, LLC, operators of dispensaries in Illinois pursuant to social equity licenses issued by Illinois regulatory authorities (together, the "LLCs"), and in 2023 the Company received an aggregate of \$10 for services rendered under the agreements. The Company sold products to the LLCs and two associated entities on a wholesale basis in the aggregate amounts of \$424, net of discounts, in the first quarter of 2023 and \$854, net of discounts, for the first quarter of 2024. Two Pointo, LLC ("Two Point") has contractual rights to purchase ownership interests in the LLCs and associated entities, subject to submitting a request for and receiving applicable Illinois regulatory approvals and other conditions. The existing owners of the LLCs and associated entities will maintain ownership interests together with Two Point. In 2023, Darren Weiss, the Company's President, received in connection with application support services rendered to an LLC in 2019, (i) a 2.73% profit interest in Two Point subject to Two Point's purchase of ownership interests in the LLCs, and (ii) a profit interest in Two Point of 0.30%, and David Spreckman, the Company's Chief Marketing Officer, received a profit interest in Two Point of 0.30% for services. All profit interests issued to Messrs. Weiss and Spreckman were voluntarily forfeited in 2024 as if they were never granted. Maria Fragias, an immediate family member of George Archos, the Company's Chief Executive Officer, is the beneficiary of a trust that holds a 7.92% ownership interest and a 3.95% profit interest in Two Point. None of the trust or such persons has received any distributions, payments, or proceeds from Two Point. As of March 31, 2024, and December 31, 2023, the amounts due from the LLCs and two associated entities were \$783 and \$443, respectively.

Leases

The Company leases real property for a retail dispensary in Aurora, Illinois from 740 Rte. 59, LLC ("740"). Pursuant to the lease agreement, the Company made payments totaling \$46 in the first quarter of 2023 and \$46 during the first quarter of 2024, which payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds an indirect 50% ownership interest in 740. Pursuant to the lease agreement, the initial term expires on June 30, 2030.

The Company leases real property for a retail dispensary in Lombard, Illinois from 783 Butterfield LLC ("783"). Pursuant to the lease agreement, the Company made payments to 783 totaling \$90 in the first quarter of 2023 and \$91 during the first quarter of 2024, which payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds a 50% indirect ownership interest in 783. Pursuant to the lease agreement, the initial term expires on January 11, 2031.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

17. SUBSEQUENT EVENTS

On April 30, 2024, the Company made a voluntary prepayment of the outstanding principal and interest under the 2022 Credit Facility in the amount of \$50,000 plus a \$1,000 prepayment premium. In connection with such voluntary prepayment, liens over certain collateral pledged by the Company were released and certain subsidiaries of the Company were released as "Credit Parties" under the 2022 Credit Facility.

On May 2, 2024, GGH filed an application with the Supreme Court of British Columbia seeking an order granting summary trial in the ongoing litigation between the Company and GGH regarding the GGH Arrangement Agreement. In the application, GGH stated it is seeking \$860,900 in damages, plus costs and interest.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management discussion and analysis (this "MD&A") of the financial condition and results of operations of the Company is for the three months ended March 31, 2024 and March 31, 2023. It is supplemental to, and should be read in conjunction with, the Company's Unaudited Interim Condensed Consolidated Financial Statements and the accompanying notes for the three months ended March 31, 2024 and with the Company's Audited Consolidated Financial Statements and the accompanying notes for the years ended December 31, 2023, 2022 and 2021 included in the Form 10-K. The financial statements referenced in this MD&A are prepared in accordance with GAAP. Financial information presented in this MD&A is presented in United States dollars ("\$" or "US\$") and expressed in thousands, unless otherwise indicated. This MD&A contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected, forecasted, or expected in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the Form 10-K. See "Cautionary Statement Regarding Forward-Looking Statements" above and "Risk Factors" in Part I, Item 1A. "Risk Factors" in the Form 10-K. The Company's management believes the assumptions underlying the Company's financial statements and accompanying notes may not be an indication of the Company's financial condition and results of operations in the future.

OVERVIEW OF THE COMPANY

Verano, one of the U.S. cannabis industry's leading companies based on historical revenue, geographical scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. An operator of licensed cannabis cultivation, processing, wholesale distribution and retail facilities, our goal is the ongoing development of communal wellness by providing responsible access to regulated medical and adult-use cannabis products to discerning customers. As of May 6, 2024, through our subsidiaries and affiliates we operate businesses in 13 states, including 139 retail dispensaries and 14 production facilities with over 1,000,000 square feet of cultivation capacity. We produce a wide variety of high quality cannabis products sold under our portfolio of consumer brands, including EncoreTM, AvexiaTM, MÜVTM, SavvyTM, BITSTM and VeranoTM. We also design, build and operate branded retail environments including Zen LeafTM and MÜVTM dispensaries that deliver a cannabis shopping experience in both medical and adult-use markets, including through Cabbage Club, an annual membership program offering exclusive benefits for cannabis consumers.

Notwithstanding the permissive regulatory environment of medical, and in some cases, also adult-use (i.e., recreational) cannabis, at the state level, it remains illegal under U.S. federal law to cultivate, manufacture, distribute, sell or possess cannabis in the U.S. Because federal law prohibits transporting any federally restricted substance across state lines, cannabis cannot be transported across state lines. As a result of current federal law prohibitions, the U.S. cannabis industry is conducted on a state-by-state basis. To date, in the U.S. 38 states plus the District of Columbia and the U.S. territories of Puerto Rico, Guam, the Commonwealth of Northern Marina Islands, and the U.S. Virgin Islands have authorized comprehensive medical cannabis programs, 24 states plus the District of Columbia and the U.S. territories of Guam, the Commonwealth of Northern Mariana Islands, and the U.S. Virgin Islands have authorized comprehensive programs for medical and adult-use (i.e. recreational) cannabis, and 11 states allow the use of low tetrahydrocannabinol and high cannabidiol products for specified medical uses. Verano operates within states where cannabis use, medical or both medical and adult-use, has been approved by state and local regulatory bodies. Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company or any of its subsidiaries.

Our strategy is to vertically integrate as a single cohesive company in multiple states through the consolidation of seed-to-sale cultivating, manufacturing, distributing, and dispensing cannabis brands and products at scale. Our cultivation, processing and wholesale distribution of cannabis consumer packaged goods are designed to support our national retail dispensary chains, and to develop and foster long-term wholesale supply relationships with third-party retail dispensary operators. Our strategy includes geographic diversity by establishing a footprint to enable us to adapt to changes in both industry and market conditions.

SELECTED RESULTS OF OPERATIONS

The following presents selected financial data derived from the (i) Unaudited Interim Condensed Consolidated Financial Statements for the three months ended March 31, 2024 and 2023 and (ii) the Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, and should be read in conjunction with the Unaudited Interim Condensed Consolidated Financial Statements and accompanying notes presented in Item 1 of this Form 10-Q. The selected Unaudited Interim Condensed Consolidated financial information below may not be indicative of the Company's future performance.

Three Months Ended March 31, 2024, as Compared to Three Months Ended March 31, 2023

| | For the Three Months Ended March 31, | | | | | |
|---|--------------------------------------|----|---------|----|-----------|--|
| (\$ in thousands) | 2024 | | 2023 | | \$ Change | |
| Revenues, net of discounts | \$ 221,306 | \$ | 227,060 | \$ | (5,754) | |
| Gross Profit | 112,960 | | 109,185 | | 3,775 | |
| Net Loss Attributable to Verano Holdings Corp. & Subsidiaries | (4,822) | | (9,237) | | 4,415 | |
| Net Loss per share – basic & diluted | (0.01) | | (0.03) | | 0.02 | |

Revenues, net of discounts

Revenues, net of discounts, for the three months ended March 31, 2024 was \$221,306, a decrease of \$(5,754) or (2.5)%, compared to revenue of \$227,060 for the three months ended March 31, 2023. Key performance drivers for retail revenue for the quarter were primarily driven by market expansion into the Maryland adult-use market which began permitting adult-use sales during July 2023, and new Zen Leaf™ store openings in the Connecticut market during the third and fourth quarters of 2023. During the three months ended March 31, 2024, the Company opened two new stores, one in Florida and one in Pennsylvania. Additionally, consistent with other multi-state cannabis operators, the Company has seen increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Retail revenue for the three months ended March 31, 2024 was approximately 66.2% of total revenue compared to 69.7% of total revenue for the three months ended March 31, 2023, in each case, excluding intersegment eliminations. Key performance drivers for cultivation (wholesale) revenues were increased third-party wholesale sales in the New Jersey market and increased adult-use third-party wholesale sales in the Maryland market, both, of which attributed to increased production output and sales of cannabis flower and cannabis related products, when compared to the three months ended March 31, 2023. Cultivation (wholesale) revenue for the three months ended March 31, 2024 was 33.8% of total revenue compared to 30.3% of total revenue for the three months ended March 31, 2023, in each case, excluding intersegment eliminations.

Gross Profit

Gross profit for the three months ended March 31, 2024 was \$112,960, representing a gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories of 51.0%. This is compared to gross profit for the three months ended March 31, 2023 of \$109,185, which represented a 48.1% gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories. The increase in gross profit during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, was attributable to higher third-party wholesale sales of Verano products, which was partially offset by increased competition and continued pricing pressure in the retail markets.

Net Loss

Net Loss attributable to the Company for the three months ended March 31, 2024 was \$(4,822), a decrease of \$4,415, compared to a net loss of \$(9,237) for the three months ended March 31, 2023. The decrease in net loss was largely driven by an overall decrease in the provision for income taxes for the three months ended March 31, 2024 compared to the three months ended March 31, 2023.

| | | For the Three Months Ended March 31, | | | | | | |
|---|----|--------------------------------------|----------|----|-----------|--|--|--|
| (\$ in thousands) | | 024 | 2023 | | \$ Change | | | |
| Cost of Goods Sold, net | \$ | 108,346 \$ | 117,875 | \$ | (9,529) | | | |
| | | | | | | | | |
| Selling, General, and Administrative Expenses | | 90,289 | 75,243 | | 15,046 | | | |
| | | | | | | | | |
| Other Income (Expense) | | (16,016) | (14,699) | | (1,317) | | | |
| | | | | | | | | |
| Provision for Income Taxes | | (11,477) | (28,320) | | 16,843 | | | |

Cost of Goods Sold, net

Cost of goods sold, net includes the costs directly attributable to cultivating and processing cannabis and for retail purchases of finished goods, such as flower, edibles, and concentrates. Cost of goods sold, net for the three months ended March 31, 2024 was \$108,346, a decrease of \$(9,529) or (8.1)%, as compared to the three months ended March 31, 2023. The decrease was primarily driven by decreased top-line revenue within the retail markets due to pricing pressure in select markets, partially offset by increased wholesale sales of Verano products to third-parties in select markets, specifically in the New Jersey adult-use market.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses ("SG&A") for the three months ended March 31, 2024 were \$90,289, an increase of \$15,046 or 20.0%, compared to SG&A expenses of \$75,243 for the three months ended March 31, 2023. SG&A expenses as a percentage of revenue was 40.8% and 33.1% for the three months ended March 31, 2024, and March 31, 2023, respectively. The increase was primarily due to a \$6,405 increase in salaries and benefits, due to increased headcounts related to new store openings, and a \$7,711 increase in general and administrative expenses primarily driven by enhancements in processes and technology, during the three months ended March 31, 2024 compared to the three months ended March 31, 2023. Additionally, SG&A expenses for the three months ended March 31, 2023 included lower stock based compensation expense compared to the three months ended March 31, 2024, driven by a prior period expense acceleration benefit during the three months ended March 31, 2023 and lower award grants during the three months ended March 31, 2023.

Other Income (Expense)

Other income (expense) for the three months ended March 31, 2024, was \$(16,016), a decrease of \$1,317 as compared to the three months ended March 31, 2023. The other income (expense) increase was primarily due to less earn out activity during the three months ended March 31, 2024 when compared to the three months ended March 31, 2023.

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. Income tax expense for the three months ended March 31, 2024, was \$(11,477), a decrease of \$16,843 or (59.5)% primarily due to impacts of prior period return to provision adjustments and a decrease in pre-tax earnings when compared to the three months ended March 31, 2023.

Results of Operations by Segment

The Company has two reportable segments: (i) cultivation (wholesale) and (ii) retail. Due to the vertically integrated nature of its business, the Company reviews its revenue at the cultivation (wholesale) and retail levels while reviewing its operating results on a consolidated basis.

The following tables summarize revenues, net of discounts, by segment for the three months ended March 31, 2024 and 2023:

| For the | Three | Mont | he Fn | hah | March 3 | 1 |
|---------|--------|--------|----------|-----|----------|---|
| roi inc | 111166 | VICTOR | 115 1711 | ucu | VIALUI 3 | |

| (\$ in thousands) | 2024 | | 2023 | | % Change | |
|----------------------------------|------|----------|------|----------|----------|--|
| Revenues, net of Discounts | | | | | | |
| Cultivation (Wholesale) | \$ | 85,906 | \$ | 80,267 | 7.0 % | |
| Retail | | 168,588 | | 184,242 | (8.5)% | |
| Intersegment Eliminations | | (33,188) | | (37,449) | (11.4)% | |
| Total Revenues, net of Discounts | \$ | 221,306 | \$ | 227,060 | (2.5)% | |

Revenues, net of discounts, for the cultivation (wholesale) segment were \$85,906 for the three months ended March 31, 2024, an increase of \$5,639 or 7.0%, compared to the three months ended March 31, 2023, in each case, excluding intersegment eliminations. The increase in cultivation (wholesale) revenues, net of discounts, was primarily driven by increased third-party wholesale sales in the New Jersey market coupled with increased adult-use third-party wholesale sales in the Maryland market, both, of which attributed to increased production output of cannabis flower and cannabis related products.

Revenues, net of discounts for the retail segment were \$168,588 for the three months ended March 31, 2024, a decrease of \$(15,654) or (8.5)%, compared to the three months ended March 31, 2023, in each case, excluding intersegment eliminations. The decrease in retail revenues, net of discounts, was primarily driven by increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Additionally, continued pricing pressure contributed to the decrease in revenues, net of discounts, when comparing the three months ended March 31, 2024 to the three months ended March 31, 2023.

Drivers of Operational Performance

Revenue

The Company derives its revenue from both its cultivation (wholesale) business in which it cultivates, produces and sells cannabis products to third-party retail customers, and its retail business, in which it directly sells cannabis products to retail patients and consumers. For the three months ended March 31, 2024, approximately 33.8% of the Company's revenue was generated from the cultivation (wholesale) business, excluding intersegment eliminations, and approximately 66.2% from the retail business, excluding intersegment eliminations. For the three months ended March 31, 2023, approximately 30.3% of revenue was generated from the cultivation (wholesale) business and approximately 69.7% from the retail business.

Gross Profit

Gross profit is revenue less cost of goods sold, net. Cost of goods sold, net includes the costs directly attributable to product sales and includes amounts paid for finished goods, such as flower, edibles, and concentrates, as well as packaging and other supplies, fees for services and processing, rent, utilities, and related costs. Cannabis costs are affected by various state regulations that limits the sourcing and procurement of cannabis products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes. Gross profit margin measures the Company's gross profit as a percentage of revenue.

The Company's expansion strategy and revenue growth have taken priority and will continue to do so for the foreseeable future as it expands its footprint, by exploring new markets and opening or acquiring new dispensary locations, and scales production within current markets. In the core markets in which the Company is already operational and, as the state markets mature, the Company anticipates that there will be pressure on margins in the cultivation (wholesale) and retail channels. The Company's current production capacity has not been fully realized and it is expected that price compression at the cultivation (wholesale) level, will be offset by operational optimization. As a result, the Company expects overall consolidated gross profit margins to gradually increase in the future.

Table of Contents

Total Expenses

Total expenses, other than the cost of goods sold, consist of selling costs to support customer relationships and to deliver product to the Company's retail stores. It also includes a significant investment in the corporate infrastructure required to support ongoing business.

Selling costs generally correlate to revenue. As a percentage of sales, selling costs are expected to increase slightly in currently operational markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia) as facility and market expansion occurs. The increase is expected to be driven primarily by the growth of the Company's retail and cultivation (wholesale) channels and the ramp up from new retail openings.

SG&A expenses also include costs incurred at the Company's corporate offices, primarily related to back-office personnel costs, including salaries, incentive compensation, benefits, stock-based compensation and professional service costs. Going forward, SG&A expenses are expected to continue in line with the Company's expansion plans. Furthermore, the Company expects to continue to incur acquisition and transaction costs related to these expansion plans and anticipates stock compensation expenses related to recruiting and hiring talent, along with legal and professional fees associated with being a public-reporting company and publicly traded in Canada and a public-reporting company in the U.S.

Provision for Income Taxes

The Company is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As the Company operates in the cannabis industry, it is subject to the limits of Section 280E of the Code under which the Company is only allowed to deduct expenses directly related to the sale of products. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code and a higher effective tax rate than most industries.

During the second quarter of 2023, Connecticut, Illinois, and New Jersey enacted tax legislation to exempt, or decouple, from Section 280E of the Code, all of which became retroactively effective as of January 1, 2023. The Company has significant operations in these states and is now permitted to deduct ordinary and necessary cannabis business expenses in these states.

LIQUIDITY, FINANCING ACTIVITIES AND CAPITAL RESOURCES

As of March 31, 2024 and December 31, 2023, the Company had total current liabilities of \$414,975 and \$412,188, respectively. As of March 31, 2024 and December 31, 2023, the Company had cash and cash equivalents of \$193,799 and \$174,760, respectively, to meet its current obligations. The Company had working capital of \$3,804 as of March 31, 2024, an increase of working capital of \$21,796 as compared to December 31, 2023. This increase in working capital was primarily driven by increased cash flow from operations of \$31,041 during the three months ended March 31, 2024.

The Company is an early-stage growth company, generating cash from revenues and deploying its capital to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and long term. Capital is primarily being utilized for capital expenditures, facility improvements, strategic investment opportunities, product development and marketing, as well as customer, supplier, and investor and industry relations. The Company takes a cautious approach in allocating its capital to maximize its returns while ensuring appropriate liquidity. While inflation and higher interest rates have not yet materially impacted the Company's business, results of operations or financial statements, given current inflation and the uncertainty of the future economic environment, the Company has taken additional measures in monitoring and deploying its capital to minimize the negative impact on its operations and expansion plans.

Liquidity Requirements

Our short-term liquidity requirements consist primarily of funds necessary to pay for our acquisitions, to repay borrowings, maintain our operations and other general business needs. We believe that internally generated funds and other sources of liquidity discussed below will be sufficient to meet working capital needs, capital expenditures, and other business requirements for at least the next 12 months. We believe we will meet known or reasonably likely future cash requirements through the combination of cash generated from operating activities, available cash balances and available borrowings. If these sources of liquidity need to be augmented, additional cash requirements would likely be financed through the issuance of equity securities or additional borrowings; however, there can be no assurances that we will be able to obtain additional equity financing or debt financing on acceptable terms in the future.

Our long-term liquidity requirements consist primarily of completing additional acquisitions, scheduled debt payments, future payments of income tax payables, maintaining and expanding our operations and other general business needs. We expect to meet our long-term liquidity requirements through various sources of capital, which may include future debt or equity issuances, net cash provided by operations and other secured and unsecured borrowings. We believe that the foregoing sources of capital will provide sufficient funds for our operations, anticipated expansion and scheduled debt payments for the long-term. Our ability to fund our operating needs will depend on our future ability to continue to generate positive cash flow from operations and our ability to obtain debt or equity financing on acceptable terms.

Table of Contents

Credit Facility

In October 2022, Verano and certain of its subsidiaries and affiliates, as the Borrowers, entered into the 2022 Credit Agreement with the lenders party thereto, pursuant to which the lenders advanced the Borrowers a \$350,000 senior secured term loan, and which also provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan of up to \$100,000; provided that the lenders elect to fund such incremental term loan. At funding, all the proceeds of the loans made under the 2022 Credit Agreement were used to repay the amounts owing under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement allows the Borrowers to (i) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (ii) incur additional mortgage financing from third-party lenders secured by real estate acquired after the initial funding of the 2022 Credit Agreement, and (iii) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 under a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, all of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions. The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default as provided in the 2022 Credit Agreement. The initially funded \$350,000 loan requires scheduled amortization payments of \$350 per month beginning in October 2023 with the remaining principal balance due in full on October 30, 2026.

At any time, the Credit Agreement Borrowers may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations, warranties and covenants and customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Credit Agreement Borrowers' ability to incur additional indebtedness and grant liens, and the ability to enter into definitive documents or consummate acquisitions or dispositions that are not otherwise permitted thereunder, among others. Additionally, the 2022 Credit Agreement requires the Credit Agreement Borrowers to meet financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of March 31, 2024, the Company was in compliance with such financial covenants.

George Archos, the Chairman and Chief Executive Officer of the Company, participated in the 2022 Credit Agreement as a lender funding \$1,000 of the \$350,000 principal amount. Mr. Archos is excluded from certain approval rights of the lenders and any penalties and fees due to Mr. Archos under the 2022 Credit Agreement are immaterial to the Company.

Tax Liabilities

The Company has U.S. income tax payable liabilities. These income tax payable liabilities will require payment from our liquidity sources, and we believe we have sufficient liquidity for both short-term and long-term payments of our income tax payable liabilities and in addition to our other obligations.

Sources and Uses of Cash

Cash Provided by (Used in) Operating Activities, Investing and Financing Activities

Net cash provided by (used in) operating, investing, and financing activities for the three months ended March 31, 2024 and 2023 were as follows:

| J | For | the | Three | Months | Ended | March 31, | |
|---|-----|-----|-------|--------|-------|-----------|--|
| | | | | | | | |

| | 101 0110 111100 11010111 2111101 1111101 0 1, | | | | | |
|---|---|----|---------|----|-----------|--|
| | 2024 | | 2023 | | \$ Change | |
| Net Cash Provided by Operating Activities | \$ 31,041 | \$ | 16,862 | \$ | 14,179 | |
| Net Cash Used in Investing Activities | \$ (9,699) | \$ | (6,725) | \$ | (2,974) | |
| Net Cash Provided by (Used In) Financing Activities | \$ (2,318) | \$ | 142 | \$ | (2,460) | |

Cash flows from Operating Activities. During the three months ended March 31, 2024 and 2023, the Company had net cash inflows of \$31,041 and \$16,862, respectively. The \$14,179 increase was mainly driven by a decrease in income taxes coupled with the tax payments made during the three months ended March 31, 2024.

Cash Flows from Investing Activities. During the three months ended March 31, 2024 and 2023, the Company had net cash outflows of \$(9,699) and \$(6,725), respectively. The \$2,974 increase in net cash outflows during the three months ended March 31, 2024 compared to the three months ended March 31, 2023 is partially driven by purchases of property, plant and equipment of \$(9,699) during the three months ended March 31, 2024, compared to purchases of property, plant and equipment of \$(8,555) during the three months ended March 31, 2023. Additionally, proceeds from the disposal of property, plant and equipment of \$1,830 during the three months ended March 31, 2023 attributed to the increase in net cash outflows when compared to March 31, 2024.

Cash Flows from Financing Activities. During the three months ended March 31, 2024 and 2023, the Company had net cash outflows of \$(2,318) and net cash inflows of \$142, respectively. The \$(2,460) decrease was driven by proceeds from the issuance of debt of \$23,710, partially offset by principal repayments of debt of \$(22,759) during the three months ended March 31, 2023, For the three months ended March 31, 2024 principal repayments of debt totaled \$(2,150).

Changes in or Adoption of Accounting Practices

Refer to the discussion of recently adopted/issued accounting pronouncements under Part I, Item 1, Notes to Unaudited Interim Condensed Consolidated Financial Statements, *Note 1 - Overview and Basis of Presentation*.

Critical Accounting Policies and Significant Judgements and Estimates

There were no material changes to our critical accounting policies and estimates from the information provided in "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in the Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risk disclosures as set forth in Part II, Item 7A of the Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as of March 31, 2024, the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Exchange Act and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures due to the material weaknesses in internal control over financial reporting identified as of December 31, 2023 and as described in Item 9A. Controls and Procedures in the Form 10-K. We believe, that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

We previously identified and disclosed material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K. These material weaknesses are currently in the process of being remediated, as of March 31, 2024. Other than the previously identified and disclosed plans to remediate the material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K, there have not been any changes in our internal control over financial reporting during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may be subject to legal proceedings, claims, investigations and government inquiries in the ordinary course of business. The Company has received, and may in the future continue to receive, claims from third parties.

Please see the Notes to the Unaudited Interim Condensed Consolidated Financial Statements, Note 11 – Contingencies and Other – Claims and Litigation, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS.

Part I, Item 1A. "Risk Factors" in our Form 10-K includes a discussion of our risk factors. There have been no material changes from the risk factors described in the Form 10-K. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future SEC filings.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

Subordinate Voting Shares

On March 19, 2024, pursuant to a merger agreement, the Company issued 31,181 Subordinate Voting Shares to the previous shareholders of WSCC, Inc, which were held back to secure indemnity obligations in connection with the Company's acquisition of WSCC, Inc. All of such Subordinate Voting Shares were issued in reliance upon the exemptions from registration afforded by Section 4(a)(2) and Rule 506(b) promulgated under the Securities Act of 1933, because (i) the issuance were not made by general solicitation or advertising and (ii) the issuances were made only to "accredited investors" (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

On March 28, 2024, Destiny Thompson, the Company's Chief People Officer, terminated a prearranged share trading plan, which was intended to satisfy the affirmative defenses of Rule 10b5-1(c) under the Exchange Act and the Company's policies regarding insider transactions. On October 9, 2023, Cristina Nuñez, a director of the Company, terminated a prearranged share trading plan, which was intended to satisfy the affirmative defenses of Rule 10b5-1(c) under the Exchange Act and the Company's policies regarding insider transactions.

Table of Contents

ITEM 6. EXHIBITS

| Exhibit Number | Description of Exhibit | | | | |
|---------------------|--|--|--|--|--|
| 3.1* | Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.1 to our Registration Statement on Form 10 filed on April 26, 2022 (File No. 000-56342) and incorporated herein by reference). | | | | |
| 3.2* | Notice of Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.2 to our Registration Statement on Form 10 filed April 26, 2022 (File No. 000-56342) and incorporated herein by reference). | | | | |
| 10.1* | Cash Incentive Plan (filed as Exhibit 10.1 to our Current Report on Form 8-K filed on March 26, 2024 (File No. 000-56342) and incorporated herein by reference). | | | | |
| 10.2* | Form of Cash Award Agreement (filed as Exhibit 10.2 to our Current Report on Form 8-K filed on March 26, 2024 (File No. 000-56342) and incorporated herein by reference). | | | | |
| 31.1** | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended | | | | |
| 31.2** | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended | | | | |
| 32.1*** | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | | | |
| 32.2*** | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | | | |
| 101.INS | Inline XBRL Instance Document | | | | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | | | | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | | | | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) | | | | |
| * Previously filed. | | | | | |
| ** Filed herewith | | | | | |

*** Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 8, 2024

VERANO HOLDINGS CORP.

By: /s/ George Archos

Name: George Archos

Title: Chief Executive Officer

By: /s/ Brett Summerer

Name: Brett Summerer

Title: Chief Financial Officer

CERTIFICATE OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George Archos, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATE OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Summerer, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three months ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, George Archos, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three months ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brett Summerer, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)